Lymphomas
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy
- Details
ClinicalTrials.gov ID:
NCT06911502
Diagnosis Type:
NA
USOR Number:
- Address
,
P: